Irlanda - engleză - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - atorvastatin calcium trihydrate - film-coated tablet - 10 milligram(s) - hmg coa reductase inhibitors; atorvastatin

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - atorvastatin calcium trihydrate - film-coated tablet - 20 milligram(s) - hmg coa reductase inhibitors; atorvastatin

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - atorvastatin calcium trihydrate - film-coated tablet - 40 milligram(s) - hmg coa reductase inhibitors; atorvastatin

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - atorvastatin calcium trihydrate - film-coated tablet - 80 milligram(s) - hmg coa reductase inhibitors; atorvastatin

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - clarithromycin - film-coated tablet - 250 milligram(s) - macrolides; clarithromycin

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - clarithromycin - film-coated tablet - 500 milligram(s) - macrolides; clarithromycin

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

sun pharmaceutical industries europe b.v. - warfarin sodium clathrate - tablet - 2.5 milligram(s) - vitamin k antagonists; warfarin - antithrombotic agent (vitamin k antagonist) - it is indicated for the prophylaxis of venous thrombosis and pulmonary embolism, and for use in the treatment of these conditions to prevent their extension and for the prophylaxis of systemic embolisation in patients with rheumatic heart disease and atrial fibrillation.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - zonisamide (unii: 459384h98v) (zonisamide - unii:459384h98v) - zonisamide 25 mg - zonisamide is indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy. zonisamide is contraindicated in patients who have demonstrated hypersensitivity to sulfonamides or zonisamide. the abuse and dependence potential of zonisamide has not been evaluated in human studies (see warnings, cognitive/neuropsychiatric adverse events subsection). in a series of animal studies, zonisamide did not demonstrate abuse liability and dependence potential. monkeys did not self-administer zonisamide in a standard reinforcing paradigm. rats exposed to zonisamide did not exhibit signs of physical dependence of the cns-depressant type. rats did not generalize the effects of diazepam to zonisamide in a standard discrimination paradigm after training, suggesting that zonisamide does not have abuse potential of the benzodiazepine-cns depressant type.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - oxcarbazepine (unii: vzi5b1w380) (oxcarbazepine - unii:vzi5b1w380) - oxcarbazepine 150 mg - oxcarbazepine tablets are indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures. oxcarbazepine tablets are contraindicated in patients with a known hypersensitivity to oxcarbazepine or to any of its components, or to eslicarbazepine acetate  [see warnings and precautions ( 5.2, 5.3 )]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to aeds, such as oxcarbazepine, during pregnancy. encourage women who are taking oxcarbazepine during pregnancy to enroll in the north american antiepileptic drug (naaed) pregnancy registry by calling 1-888-233-2334 or visiting http://www.aedpregnancyregistry.org/. risk summary there are no adequate data on the developmental risks associated with the use o

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - pantoprazole sodium (unii: 6871619q5x) (pantoprazole - unii:d8tst4o562) - pantoprazole sodium for delayed-release oral suspension is indicated for: pantoprazole sodium for delayed-release oral suspension is indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis (ee). for those adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of pantoprazole sodium for delayed-release oral suspension may be considered. safety of treatment beyond 8 weeks in pediatric patients has not been established. pantoprazole sodium for delayed-release oral suspension is indicated for maintenance of healing of ee and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with gerd. controlled studies did not extend beyond 12 months. pantoprazole sodium for delayed-release oral suspension is indicated for the long-term treatment of pathological hypersecretory conditions, including zollinger-ellison (ze) syndrome. - pan